<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019782</url>
  </required_header>
  <id_info>
    <org_study_id>R-2018-785-041</org_study_id>
    <nct_id>NCT04019782</nct_id>
  </id_info>
  <brief_title>Collagen-PVP vs Hylan G-F 20 in the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Efficacy Evaluation of Intraarticular Collagen-polyvinyl Pyrrolidone (Fibroquel®) vs Hylan G-F 20 (Synvisc®) in the Treatment of Knee Osteoarthritis. A Double-blind, Controlled, Randomised, Parallel-group Non-inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Articular cartilage degradation is the main characteristic of osteoarthritis (OA), involving
      enzymatic and inflammatory mechanisms that change it into a chronic disease. Since articular
      cartilage shows limited regenerative ability, several intra-articular drugs have been
      developed in order to decrease inflammation and provide a better clinical outcome to the
      patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to compare effectiveness of the treatment with intra-articular administration
      of collagen-PVP versus hylan GF 20, using the International Knee Documentation Committee
      (IKDC) score, 6 months after treatment. Hypothesis to test is: If effectiveness of
      intra-articular collagen-PVP is not lower than hylan GF 20 treatment in knee osteoarthritis
      subjects, then, statistically significant difference would not exist in IKDC score mean
      increase among treatment groups, after six months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants in one group receive drug A (Hylan G-F20) &quot;in parallel&quot; to participants in the other group, who receive drug B (Collagen-PVP).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Double-blind masking.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>International Knee Documentation Committee (IKDC).</measure>
    <time_frame>Evaluation will be conducted at Baseline and 6 months after first infiltration</time_frame>
    <description>Change from Baseline in International Knee Documentation Committee (IKDC) subjective score at 6 months. The IKDC subjetive form is a patient-reported outcome, which contains sections on knee symptoms (7 items), function (2 items), and sports activities (2 items).The IKDC is scored by summing the scores for the individual items and then transforming the score to a scale that ranges from 0 to 100 (add the score for each item and divide by the maximum possible). The transformed score is interpreted as a measure of function such that higher scores represent higher levels of function and lower levels of symptoms. A score of 100 is interpreted to mean no limitation with activities of daily living or sports activities and the absence of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Intensity</measure>
    <time_frame>Evaluation will be conducted at Baseline, 2 months, 3 months and 6 months after first infiltration</time_frame>
    <description>Change from Baseline in Pain Intensity score (MOS Pain severity scale) at 6 months. The Medical Outcomes Study (MOS) Pain Severity Scale is a 5-item scale to assess pain intensity (average and at the most), frequency, and duration over the last 7 days. Scores range from 0-100; higher score indicates more pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life: EQS-5D</measure>
    <time_frame>Evaluation will be conducted at Baseline, 2 months, 3 months and 6 months after first infiltration</time_frame>
    <description>Change from Baseline in quality of life (EQS-5D) score at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Urine Collagen Type II C-telopeptide Fragments</measure>
    <time_frame>Evaluation will be conducted at Baseline, and 6 months after first infiltration</time_frame>
    <description>Changes from baseline in Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Gonarthrosis</condition>
  <arm_group>
    <arm_group_label>Collagen-PVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collagen-polyvinyl pyrrolidone (collagen-PVP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hylan G-F 20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hylan G-F 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Collagen-PVP</intervention_name>
    <description>Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)</description>
    <arm_group_label>Collagen-PVP</arm_group_label>
    <other_name>Fibroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hylan G-F 20</intervention_name>
    <description>Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)</description>
    <arm_group_label>Hylan G-F 20</arm_group_label>
    <other_name>Synvisc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 40 and 80 years old

          -  Osteoarthritis in the knee rated II or III (Kellgren-Lawrence Grading Scale).

          -  Pain intensity (MOS Pain Severity Scale) greater than 40.

          -  Subject able to understand, co-operative and reliable.

          -  Written informed consent.

        Exclusion Criteria:

          -  Acute arthritis in the knee.

          -  Ongoing anticoagulant therapy.

          -  Skin infection at the injection site.

          -  Systemic or intraarticular (target knee) corticosteroids in the past 3 months.

          -  Viscosupplementation (target knee) in the past year

          -  Arthroscopy/osteotomy/surgery in the past 5 months (target knee).

          -  Any surgery scheduled in the next 6 months

          -  Concomitant rheumatic disease (rheumatoid arthritis, spondyloarthritis, systemic lupus
             erythematosus, fibromyalgia).

          -  Severe varus/valgus deformity (&gt;15°).

          -  Frontal deformity greater than 20 degrees

          -  History of allergy or hypersensitivity to hyaluronic acid or avian proteins

          -  History/present evidence of: metabolic joint diseases; crystal arthropaties;
             ochronosis; acromegaly; haemochromatosis; Wilson's disease; primary
             osteochondromatosis; heritable disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriel J Horta-Baas, MD, Msc</last_name>
    <phone>529998360846</phone>
    <email>gabho@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Romero-Figueroa, MD, PhD</last_name>
    <email>sromero61@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gabriel Horta Baas</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel J Horta Baas, MD, Msc</last_name>
      <phone>529993860846</phone>
      <email>gabho@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Furuzawa-Carballeda J, Muñoz-Chablé OA, Barrios-Payán J, Hernández-Pando R. Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study. Eur J Clin Invest. 2009 Jul;39(7):591-7. doi: 10.1111/j.1365-2362.2009.02154.x.</citation>
    <PMID>19453649</PMID>
  </reference>
  <reference>
    <citation>Furuzawa-Carballeda J, Muñoz-Chablé OA, Macías-Hernández SI, Agualimpia-Janning A. Effect of polymerized-type I collagen in knee osteoarthritis. II. In vivo study. Eur J Clin Invest. 2009 Jul;39(7):598-606. doi: 10.1111/j.1365-2362.2009.02144.x. Epub 2009 Apr 23.</citation>
    <PMID>19397687</PMID>
  </reference>
  <reference>
    <citation>Furuzawa-Carballeda J, Lima G, Llorente L, Nuñez-Álvarez C, Ruiz-Ordaz BH, Echevarría-Zuno S, Hernández-Cuevas V. Polymerized-type I collagen downregulates inflammation and improves clinical outcomes in patients with symptomatic knee osteoarthritis following arthroscopic lavage: a randomized, double-blind, and placebo-controlled clinical trial. ScientificWorldJournal. 2012;2012:342854. doi: 10.1100/2012/342854. Epub 2012 Apr 1.</citation>
    <PMID>22545014</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Intraarticular Injections</keyword>
  <keyword>Viscosupplementations</keyword>
  <keyword>Type I Collagen</keyword>
  <keyword>Patient Outcome Assessment</keyword>
  <keyword>Patient Reported Outcome Measures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

